Skip to Main Content

In the latest bid to speed cancer therapies from the lab to patients, Regeneron Pharmaceuticals (REGN) and Bluebird Bio (BLUE) announced Monday they had reached a five-year deal to discover, develop, and market new treatments by combining their individual technologies.

The agreement, which will initially focus on a half-dozen targets, is a strategic gambit by each company to further expand their R&D operations in oncology, the hottest — and most competitive — field in the biopharmaceutical industry.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED